Phosphodiesterase 5 (PDE5) has been identified in many species. The three isoforms, PDE5A1, PDE5A2, and PDE5A3, differ only in their N-terminal sequence. PDE5A1 and PDE5A2 are ubiquitous, but PDE5A3 is specific to smooth muscle. The initial three exons (A1-A3-A2) of PDE5A, located on chromosome 4q26, are alternative first exons encoding the isoform-specific sequences. The PDE5A promoter overlaps with the A1-specific exon, while the PDE5A2 promoter is located between the A3-and A2-specific exons. Both respond to cyclic guanosine monophosphate (cGMP) or cyclic adenosine monophosphate (cAMP) stimulation. The PDE5A2 promoter contains an Sp1-binding sequence critical for basal and cGMP/cAMP-inducible promoter activities. PDE5A is induced by adjacent sequences (enhancers) containing Sp1-binding sites. The potential role of PDE5A promoters in the tachyphylaxis effect of PDE5 inhibitors is currently being investigated. Preliminary data suggest that hypoxia might down-regulate PDE5A promoters, implying an involvement of PDE5 in stuttering priapism.
Introduction
First purified from rat lung, phosphodiesterase 5 (PDE5) has now been identified in many species and in a wide variety of tissues (Table 1) . Whether PDE5 is expressed in the heart has been a subject of controversy. All studies using either RT-PCR or Northern blot have demonstrated PDE5 mRNA expression in the heart, [1] [2] [3] [4] [5] and a separate study using immunohistochemical staining and functional assays also demonstrated PDE5 expression in canine cardiomyocytes. 6 However, PDE5 enzymatic activity was reported to be absent in a human ventricular homogenate. 7 Two PDE5 isoforms, PDE5A1 and PDE5A2, have been identified in humans and dogs. 1, 4 More recently, a third isoform, PDE5A3, was identified in humans. 8 The three human PDE5 isoforms differ only in the 5 0 end of the mRNA and the corresponding N-terminal of the protein.
8 PDE5A1, PDE5A2, and PDE5A3 share similar cyclic guanosine monophosphate (cGMP)-catalytic activities that are differentially inhibited by sildenafil or zaprinast, with PDE5A1 being more resistant to such inhibition than PDE5A2 or PDE5A3.
While PDE5A1 and PDE5A2 are found in nearly all tissues, with PDE5A2 being more widespread, the distribution of PDE5A3 is limited to smooth muscle ( Table 2 ). PDE5A2 expression is identifiable in virtually all cells cultured from breast and uterine cancers, leukemia, fibrosarcoma, fibroblasts, aortic smooth muscle, bladder smooth muscle, urethral smooth muscle, penile smooth muscle, penile endothelium, and aortic endothelium (Table 3 ). In contrast, PDE5A1 expression is either absent or minimal in the same cultured cells. In cultured cells, PDE5A3 expression retains its smooth musclespecificity ( Table 3) .
The human PDE5 gene is located on chromosome 4q26 4, 5 and initially reported to contain 21 exons spanning approximately 100 kilobases. 5 The current identification of PDE5 isoforms should increase that number to 23 exons, with the first three exons being alternative first exons encoding the isoformspecific sequences. These three alternative first exons are arranged in the order of A1-A3-A2 in the PDE5A gene. 8 Analysis of gene fragments preceding each of these three exons identified two promoters: one preceding and overlapping with the A1-specific exon (the PDE5A promoter) and another preceding the A2-specific exon (the PDE5A2 promoter). 8, 9 The PDE5A promoter consists of a 139-bp core with full basal activity, a 308-bp upstream enhancer, and a 156-bp downstream enhancer. The enhancers confer additive cyclic nucleotide-inducible activities to the basal promoter. Four AP2-and two Sp1-binding sites are identified in the upstream enhancer, and four Sp1-binding sites in the downstream enhancer. These transcription factor-binding sites are likely to mediate the cyclic nucleotide-inducible promoter activities.
The PDE5A2 promoter is 182 bp in length and contains one AP2-and three Sp1-binding sequences. 10 Mutagenesis of the AP2-binding site only slightly impacts the basal or inducible promoter activity. Mutagenesis of the 5 0 Sp1-binding site reduces both 
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the basal and inducible promoter activities by approximately 50%, whereas mutagenesis of the remaining two Sp1-binding sites, which overlap by one nucleotide, completely abolishes either the basal or the inducible promoter activity. The basal or the inducible promoter activity of the PDE5A2 promoter is approximately one-third of its counterpart in the PDE5A promoter. Having two promoters to initiate its transcription probably explains why PDE5A2 is the predominant isoform. The inducibility of PDE5A and PDE5A2 promoters by cGMP suggests that increased cGMP levels resulting from the administration of PDE5 inhibitors may increase the expression of PDE5. 10 As this feedback loop ensues, increasing dosages of PDE5 inhibitors may be required to produce the desired therapeutic effect over the long term. While sildenafil has been prescribed for more than 5 y, whether its chronic use produces such a tachyphylaxis effect is still being assessed. In cell cultures, only a very large dose (25 mM) of sildenafil increases PDE5 expression. 11 Because such a dosage is clinically irrelevant, there appears to be no need to suggest revised prescribing guidelines for the therapeutic application of PDE5 inhibitors.
Patients with sickle-cell disease are prone to recurrent priapism. 12 It is known that during prolonged, normal erection, the static blood within the corporal sinuses gradually loses oxygen tension and pH. 13 In this relative hypoxic and acidic environment, the erythrocytes of the sicklemic patients become more sickled, further sludge the outflowing veins, and thus worsen the hypoxic condition. As this vicious cycle of tissue hypoxia and erythrocyte sickling ensues, ischemic priapism develops.
14 Indeed, it is generally agreed that most cases of stuttering priapism, characterized as repeated self-resolving periods lasting from 20 min to 3 h, occur after one episode of ischemic priapism.
As PDE5 plays critical roles in returning the relaxed cavernous smooth muscle to the contracted state, its expression could be affected by anoxia and thus linked to ischemic and stuttering priapism. By culturing cavernous smooth muscle cells under anoxic conditions, PDE5 mRNA is greatly diminished. 11 By restricting blood flow to the cavernous tissue following ligation of the pudendal arteries in the rat, PDE5 expression decreases gradually over a course of 1-6 weeks post-ligation. These results support the notion that ischemic priapism is associated with down-regulation of PDE5 expression. 11 
